Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Cero Therapeutics Holdings Inc (CERO)

Cero Therapeutics Holdings Inc (CERO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Cero Therapeutics Holdings Inc 201 Haskins Way Suite 230 South San Francisco CA 94080 USA

www.cero.bio Employees: 8 P: 650-407-2376

Sector:

Medical

INDUSTRY GROUPING:

Medical - Drugs

Description:

CERo Therapeutics Holdings Inc. is an immunotherapy company advancing the development of next generation engineered T cell therapeutics for the treatment of cancer. The company's lead product candidate includes CER-1236. CERo Therapeutics Holdings Inc., formerly known as Phoenix Biotech Acquisition Corp., is based in OAKLAND, Calif.

Key Statistics

Overview:

Market Capitalization, $K 911
Enterprise Value, $K 761
Shares Outstanding, K 20,803
Float, K 20,728
% Float 99.64%
Short Interest, K 22
Short Float 0.11%
Days to Cover 1.00
Short Volume Ratio 0.72
% of Insider Shareholders 0.36%
% of Institutional Shareholders 29.64%

Financials:

Annual Sales, $ 0 K
Annual Net Income, $ -8,300 K
Last Quarter Sales, $ 0 K
Last Quarter Net Income, $ -4,860 K
EBIT, $ -16,130 K
EBITDA, $ -14,970 K

Growth:

1-Year Return -99.89%
3-Year Return -100.00%
5-Year Return 0.00%
5-Year Revenue Growth 0.00%
5-Year Earnings Growth 0.00%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -9.10 on 11/19/25
Next Earnings Date 02/18/26 [--]
Earnings Per Share ttm -102.61
EPS Growth vs. Prev Qtr 85.25%
EPS Growth vs. Prev Year 94.94%
Annual Dividend & Yield (Paid) 0.00 (0.00%)
Annual Dividend & Yield (Fwd) 0.00 (0.00%)
Dividend Payout Ratio 0.00%
Most Recent Split 1-20 on 06/13/25

CERO Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % 0.00%
Return-on-Assets % -241.96%
Profit Margin % 0.00%
Debt/Equity 0.00
Price/Sales N/A
Price/Cash Flow N/A
Price/Book N/A
Book Value/Share -3.75
Interest Coverage -0.09
60-Month Beta 0.27
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar